İntravenöz Trombolitik Tedavi Verilen Akut İskemik İnmeli Hastaların Değerlendirilmesi; Bir İnme Merkezinin Deneyimleri

Abstract

INTRODUCTION: Intravenous thrombolytic (iv-tPA) treatment is a recommended treatment in acute ischemic stroke (AIS). We aimed to evaluate the effectiveness and side effects of this treatment on our patients. METHODS: We retrospectively evaluated the datas of patients with AIS treated with 0,9 mg/kg iv-tPA between 2018-2020. RESULTS: Forty-nine patients were treated with iv-tPA between 2018 and 2020. NIHSS scores at 24th hour were found significantly decreased compared with at onset(8,3±4,1 at onset, 4,9±5,1 at 24th hour, p=0,000). Thirty-eight (%77,6) patients had good clinical outcome. Intracerebral hemorrhage (ICH) was spotted in 3 (6,1%) patients. Systolic blood pressure (ICH group: 163±59 mmHg, non-ICH group: 141±25 mmHg p=0,014), serum glucose level(ICH group: 173±117 mg/dl, non-ICH group: 124±45mg/ dl, p=0,007) and mean door-needle time (ICH group: 125±9 min., non-ICH group: 137±54 min. p=0,029) were found significantly increased in patients with ICH. Total 4 (8,2%) patients died after iv-tPAtreatment. DISCUSSION AND CONCLUSION: Our study showed that iv-tPA improves the clinical findings of AIS. Additinally high serume glucose level and systolic blood pressure may increase the risk of ICH.